Is the amyloid concentration in AD clinical trials rational given lecanemab's approval, or should the field pivot aggressively to neuroinflammation?

Clinical Trial Landscaping for Alzheimer's Disease Therapeutics

2026-04-16 View full analysis →

0.39

Quality Score

0

Rounds

3

Hypotheses

2

Surviving

120s

Duration

Debate Transcript

No transcript rounds recorded for this debate.